THERIMMUNE RESEARCH CORPORATION
THERIMMUNE RESEARCH CORPORATION
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1998-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Website Url:
http://www.therimmune.com
Status:
Closed
Similar Organizations
Aveva Drug Delivery Systems
Aveva Drug Delivery Systems is a pharmaceuticals company that offers transdermal drug delivery services.
Free at Last
Free at Last is a company that provides drug rehabilitation services.
PolarisRx
PolarisRx is a company that provides pharmacy services.
Premier Source
Premier Source, a privately held company that provides consulting and reimbursement services to medical device.
Official Site Inspections
http://www.therimmune.com
- Host name: 199.59.243.227
- IP address: 199.59.243.227
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "TherImmune Research Corporation"
Tharimmune, Inc | Immunology & Inflammation …
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company’s lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus …See details»
About Tharimmune, Inc. | Pioneering Biotech Solutions
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company’s lead clinical-stage asset, TH104, has been observed to suppress chronic, …See details»
Tharimmune, Inc. - LinkedIn
Tharimmune, Inc. (Nasdaq: THAR) is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing ...See details»
About - Tharimmune, Inc.
Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known …See details»
Hillstream BioPharma Progressing Towards Acquiring …
Sep 22, 2023 Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases announced a corporate name change ...See details»
Tharimmune, Inc. (THAR) Company Profile & Facts - Yahoo Finance
See the company profile for Tharimmune, Inc. (THAR) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Tharimmune, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Jun 20, 2023 About Tharimmune Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The …See details»
Immunology - Tharimmune, Inc
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company’s lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus …See details»
Tharimmune - Crunchbase Company Profile & Funding
Organization. Tharimmune . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Tharimmune is a development-stage company …See details»
Intract Signs Nonbinding Letter of Intent to Merge with …
Sep 30, 2024 About Tharimmune. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The …See details»
Tharimmune Signs Nonbinding Letter of Intent to Merge With …
Sep 30, 2024 Tharimmune, Inc. [email protected]. LHA Investor Relations Tirth T. Patel [email protected]. Contact Information. Tirth Patel LHA Investor …See details»
Tharimmune Announces Option Agreement for Key Technologies …
Apr 23, 2024 Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company's lead clinical …See details»
Tharimmune, Inc. (THAR) Stock Price, News, Quote & History
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre …See details»
Tharimmune Announces Upcoming Conference Presentations
Oct 25, 2024 BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company …See details»
Lynne A Bui, MD - Tharimmune, Inc
She is also the Founder and Chairman of GCRI Foundation, a non-profit organization dedicated to funding clinical research in cancer; and a former Fellow of the Leukemia & Lymphoma Society, …See details»
Tharimmune Acquires Global Exclusive License to Develop INT …
Sep 16, 2024 Tharimmune, Inc. (NASDAQ: THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation …See details»
Tharimmune Executes Exclusive Global Licensing Agreement for …
Nov 6, 2023 Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis Tharimmune, Inc. Mon, Nov 6, 2023, 2:35 PM 5 min readSee details»
Cary biotech startup lands licensing deal for potential chronic itchy ...
Nov 15, 2023 Tharimmune Inc. in Bridgewater, N.J., announced Nov. 6 it had executed a global licensing agreement with Avior for the Cary company’s AV104 therapy. AV104 is an oral thin …See details»
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical …
Feb 5, 2024 Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis Tharimmune, Inc. Mon, Feb 5, …See details»
Tharimmune Announces Positive Results of Phase 1 Trial in …
Jun 10, 2024 Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis …See details»